Jacob Johnson
Stock Analyst at Stephens & Co.
(2.86)
# 1,581
Out of 5,241 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $212.11 | +13.15% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $6.90 | -13.04% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $4.40 | +36.36% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $16.02 | +274.53% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $161.91 | +94.55% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $438.34 | +55.13% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $102.87 | +65.26% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $3.51 | +42.45% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.04 | +957.69% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $17.99 | +111.23% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $13.14 | +29.38% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.34 | +6.84% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $43.30 | +100.92% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $302.89 | +28.76% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $8.24 | +118.45% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $2.46 | +143.90% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $20.76 | +39.69% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $213.21 | -39.03% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $150.85 | +149.92% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $212.11
Upside: +13.15%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $6.90
Upside: -13.04%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $4.40
Upside: +36.36%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $16.02
Upside: +274.53%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $161.91
Upside: +94.55%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $438.34
Upside: +55.13%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $102.87
Upside: +65.26%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.51
Upside: +42.45%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.04
Upside: +957.69%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $17.99
Upside: +111.23%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $13.14
Upside: +29.38%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.34
Upside: +6.84%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $43.30
Upside: +100.92%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $302.89
Upside: +28.76%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $8.24
Upside: +118.45%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $2.46
Upside: +143.90%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $20.76
Upside: +39.69%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $213.21
Upside: -39.03%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $150.85
Upside: +149.92%